Day: June 5, 2021
Tedizolid
Introduction: Tedizolid phosphate is an oxazolidinone approved for the treatment of acute bacterial infections of the skin and skin structure (ABSSSI) and active against methicillin-resistant Staphylococcus aureus. Objectives: The objective of this article was to review the evidence for the efficacy and safety of tedizolid phosphate for the treatment of ABSSSI. Review of evidence: Approval […]
Read More
Istaroxime hydrochloride
General description: Product group: Chemicals Category: Other CAS No: 374559-48-5 Properties: Purity:> 98% Molecular Formula: C21H33ClN2O3 Molecular weight: 396.95 UNSPSC: 12352200 Scientific information: Istaroxime Hcl (PST-2744 Hcl) is a positive inotropic agent that mediates its action by inhibiting sodium / potassium adenosine triphosphatase (Na + / K + ATPase). IC50 value: 0.43 +/- 0.15 uM […]
Read More
Brassinolide
Resume We conducted field and pot experiments to investigate the effects of brassinolide on 1-year-old Robinia pseudoacacia L. seedlings. In the field experiment, the roots of the seedlings were soaked in brassinolide solutions containing 0–0.4 mg / l of pure brassinolide before planting. Seedling survival and growth were determined 8 months later. The results showed […]
Read More
Ruxolitinib (INCB018424)
Background Ruxolitinib dihydrochloride is a specific inhibitor of Janus-associated kinase (JAK1 and JAK2). Ruxolitinib is a small molecular with the formula C17H21N6O4P and a molecular weight of 404. Ruxolitinib phosphate is a cyclopentyl propionitrile derivative competitive with administered ATP and shows inhibitory activity on JAK1 and JAK2. Ruxolitinib inhibits phosphorylation of JAK1 / 2, STAT5, […]
Read More
PCI-32765, BTK Inhibitor
Resume Small molecule drugs that target the B-cell antigen receptor (BCR) signalosome show clinical efficacy in the treatment of B-cell non-Hodgkin lymphoma. These agents, including Bruton’s tyrosine kinase (BTK) inhibitor PCI -32765, show an unexpected response in patients with chronic lymphocytic leukemia (CLL): a rapid and sustained reduction in lymphadenopathy accompanied by transient lymphocytosis, which […]
Read More